TECX News & Events

"Our team continued to advance our lead asset TX45 with the positive topline data from Part B of our Phase 1b study in patients with HFrEF. Following our recent presentation of the full Part A data set at the ESC Heart Failure 2025 Congress, the improvements demonstrated in both left heart function and pulmonary hemodynamics across both PH-HFrEF and PH-HFpEF populations suggest TX45 has the potential to be effective in a broad patient population," said Alise Reicin, M.D., President and Chief Executive Officer of Tectonic. "Enrollment continues in our global APEX Phase 2 trial in PH-HFpEF, and we expect to report topline results from that study in 2026."

Truist analyst Danielle Brill notes that shares of Tectonic Therapeutic (TECX) are off by greater than 30% following Eli Lilly's (LLY) data presentation and publication from their failed study in heart failure with preserved ejection fraction patients with recombinant long acting relaxin mimetic, volenrelaxin. The negative news "represents another hit to the emerging relaxin class of drugs," but the firm also notes that read-through should be limited as the population enrolled in Lilly's trial is distinct from those enrolled in Tectonic's. The firm, which believes Tectonic's approach of targeting Combined Post- and Pre-Capillary Pulmonary Hypertension has "the strongest rationale" and calls selloff "overdone," keeps a Buy rating and $64 price target on Tectonic shares.